Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Curr Oncol Rep
; 22(6): 57, 2020 05 16.
Article
em En
| MEDLINE
| ID: mdl-32415339
Palavras-chave
Abemaciclib; Alpelisib; Aromatase inhibitor; Aurora kinase inhibitor; Biomarkers; CDK inhibitor; CDK4/6 inhibitor; Clinical trials; ESR1; Endocrine therapy; Estrogen receptor-positive (ER+) breast cancer; Everolimus; FGFR inhibitor; Fulvestrant; Hormone receptor-positive (HR+) and HER2-negative (HER2−) breast cancer; Metastatic breast cancer (MBC); PI3K inhibitor; PIK3CA; Palbociclib; RB1; Resistance mechanisms; Ribociclib; Selective estrogen receptor downregulator (SERD); Sequencing of therapy; Targeted therapy; mTOR inhibitor
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Inibidores de Proteínas Quinases
/
Quinase 4 Dependente de Ciclina
/
Quinase 6 Dependente de Ciclina
Limite:
Female
/
Humans
Idioma:
En
Revista:
Curr Oncol Rep
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos